What is your assessment of the current state of the science? Has the field matured and really started making major contributions to public health, or is that high value in terms of translation still just over the horizon? BIRNBAUM: I think there's always more we can do, but I think that we've had some major successes. I could think of the example of lead, where the basic research that was done led to an understanding of the fact that there is really no safe level for lead and has led to regulations which have had a major impact in our seeing dramatic drops in the level of blood lead in most of our population.
In addition, there's a lot of stuff that's been done with air pollution, where we now understand that effects are being observed in people at lower amounts, lower levels of air pollution than we ever thought were dangerous before. And we're also getting a better handle on what air pollution might do to people. For many years we focused on the effects on the lung and respiratory disease, but we're beginning to understand that certain kinds of air pollution really target the heart and our vascular system. We're also beginning to understand that exposure to air pollutants to embryos or young children can in fact have long-lasting effects on their health. So, I think those are just a few-I mean, I could cite many other examples. Asthma is another example where we're getting much better understanding that, for example, there are things that we can do to help reduce the incidence of asthma in people. For example, living in the inner cities, where you have high levels of pollution from dust mites or cockroaches, if we can clean up the homes, we can do a lot better.
HOOD:
What do you see as the major unanswered questions in the field today, and how can the NIEHS effectively contribute to finding answers to those questions? BIRNBAUM: Well, I think the questions are almost unlimited, as are the answers, and I think we have to have a systematic, consistent approach where we try to say what is the real question that we're trying to answer, and not always ask the same questions that we've asked in the past. So we need to think more broadly. The example I said a minute ago about the cardiovascular effects of air pollution-those are things that we never even thought about until maybe 10 years ago, when in fact we began to see… It was really led by epidemiology studies, studies of human populations, showing that there was increased mortality and hospital visits, for example, at times of serious air pollution, which tended to drop when there wasn't air pollution. And when we began to find out what was really causing these problems, it turned out to be heart disease. So then we went back, and we did animal models so that we could get a better understanding of what caused this.
I think some of the key areas that we're focusing on are the issues at the intersection between the environment and genetics, so that we're beginning to understand that if we do an epidemiology study in a large population, and we can see a risk but it's very limited, if we knew who the real people were at risk, we might find a very high risk in that percentage of the population. And that's because we all have slightly different genes, which can in fact impact how we respond to different kinds of exposures. So that's a very key area.
I think another very key area that we need to be thinking about is the impact of climate change on health. Climate change is going to bring around changes in temperatures, changes in floods and droughts, changes in exposure to chemicals, changes in infectious disease, and we need to be primed to understand what those effects may be so we can begin to develop preventative strategies to avoid health effects.
Dr. Birnbaum, as the director of an institute responsible for a $730 million budget and some 1,240 research grants, iii do you anticipate the opportunity to encourage more multidisciplinary teamwork in the environmental health sciences research enterprise?
BIRNBAUM: Well, the answer to that last question is: absolutely. I think, again, when we're dealing with complex questions and complex diseases, we need to bring all the best minds we can to bear upon the question. And these kinds of complex problems require a multidisciplinary approach and teams of people getting together.
My approach in science leadership is to empower my staff. 
